about
ANKHD1, ankyrin repeat and KH domain containing 1, is overexpressed in acute leukemias and is associated with SHP2 in K562 cellsSerine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.Tissue factor-dependent coagulation activation by heme: A thromboelastometry study.Identification of protein-coding and non-coding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts.Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatinScreening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome.Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores.Endothelial activation by platelets from sickle cell anemia patients.Elevated hypercoagulability markers in hemoglobin SC disease.Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.Improving the differential diagnosis between myelodysplastic syndromes and reactive peripheral cytopenias by multiparametric flow cytometry: the role of B-cell precursors.Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyureaCytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemiaStathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cellsLow Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms.IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.PTK2 and PTPN11 expression in myelodysplastic syndromes.CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12.De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.Characterization of Human AB Serum for Mesenchymal Stromal Cell Expansion.Updates in cytogenetics and molecular markers in MDS.Stathmin 1 in normal and malignant hematopoiesis.Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway.Differential profile of PIP4K2A expression in hematological malignancies.ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells.ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells.Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells.Elevated plasma levels and platelet-associated expression of the pro-thrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease.Reactive oxygen species overload promotes apoptosis in JAK2V617F-positive cell lines.Myelodysplastic syndrome with synchronous gastric cancer: when the symptoms suggest something else.ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells.Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.Fetal hemoglobin and hemolysis markers in sickle cell anemia.Stathmin 1 expression in plasma cell neoplasms.BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine.Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms.
P50
Q28262135-12A3128A-5F5E-4BF9-8075-327F3C60538FQ33588161-8A93BBAE-E43C-44EC-B389-44B7B7A1747DQ33596569-27544CA9-2EB2-4D1D-9F1F-7841081DEB4FQ33596569-D0AAF6B5-E54D-4FC6-B590-86F48425AFA8Q33633465-B8590F9E-3291-40CB-9F8B-F81044B392F5Q34384728-FBC4C920-454D-4BFD-BF4E-EBB2E3ABCCE3Q34750520-CE82BADD-F327-48DB-9D19-744939BB7E04Q35028968-D03A33F9-64B9-429D-AD89-DCC0762FBC61Q35049152-DA594454-6331-476F-ABCC-EBF92730616FQ35063862-D84A4B82-0067-4B2E-B9A3-BF54C9375F48Q35097680-E4D9553D-DA7A-4C5E-AFF8-8530FC549CF2Q35236050-94C29BAF-68B1-4DB1-9ADE-706BD3E35BEEQ35346433-8A616405-6882-4E2D-BB13-1C6104A4FA3CQ35596082-58F22803-D356-468E-92BD-93A8FEA2E42CQ35669858-55332646-2D81-4D37-8212-76140E66B832Q35881223-D1B19354-77C2-4BC1-9CAD-3464B1450AD9Q36333518-93365119-B079-4BD0-815D-88961502604CQ36498395-802A2FC9-1ACC-4A44-885C-16BC1278F090Q36557368-23D54D8A-2D60-4DE0-BAD0-42A280110211Q36691624-14B169F0-288F-4931-AE6C-22641F32838AQ36916389-0EC78172-A719-4131-A28F-373C9D3E37F4Q37234608-C60D7577-CED6-430B-B322-273EF8A7F884Q37538138-7C25EAF9-AC27-4CE4-96F5-DA9855CA2BDBQ37584726-41E16EFD-87DD-45F0-B7C1-861BEDBEFDABQ37654981-19B8C543-9712-460C-8B47-40E1B0C98172Q37845723-29E95B87-E113-45E8-8D08-12B8B7A69368Q38199283-182D2441-F597-4583-875A-33AD549676E8Q38795770-94341111-F1A3-4167-AC52-67F2F18123AAQ38847696-D468C4DD-0426-48A7-89BA-038CCB8EC82EQ39004834-3A707BC1-6049-4B56-AEE3-A82F4EBCC018Q39234913-A6F06F53-4F7C-432F-86F8-8BE2DD023157Q39543191-CE171ED8-8946-4D12-AF64-48EB722988F7Q39589473-B448B057-FF77-4C51-8607-A7C54D3077BEQ41186755-8FB3F258-8177-4FE5-89DF-1AEA75EB3637Q41631253-6D33394F-3946-4F4A-9AAC-72CD1ED6AF06Q41671217-94D2C5A5-C4F7-4395-A306-5F6D5FAB3D61Q41754225-AB90C791-1155-4BCE-8903-B7D7A0F1BAC7Q41968140-B7A31A40-BC13-42E8-8595-2407BACC806BQ42342978-EE7CC568-ABB5-41F7-BAA4-B7C6973B844EQ42362055-1E7B0AB0-D55E-488A-85B4-EA2DF0042A71
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Fabiola Traina
@ast
Fabiola Traina
@en
Fabiola Traina
@es
Fabiola Traina
@nl
Fabiola Traina
@sl
type
label
Fabiola Traina
@ast
Fabiola Traina
@en
Fabiola Traina
@es
Fabiola Traina
@nl
Fabiola Traina
@sl
prefLabel
Fabiola Traina
@ast
Fabiola Traina
@en
Fabiola Traina
@es
Fabiola Traina
@nl
Fabiola Traina
@sl
P106
P1153
6701314769
P31
P496
0000-0003-4258-289X
P6023
2101205902